Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial.
Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial.
复制标题
DOI：
10.1111/jvim.14726
复制
发表时间：
2017-07
影响因子：
2.6
通讯作者：
Strehlau G
中科院分区：
文献类型：
--
作者：
King JN;Font A;Rousselot JF;Ash RA;Bonfanti U;Brovida C;Crowe ID;Lanore D;Pechereau D;Seewald W;Strehlau G
慢性肾脏病（CKD）是犬发病和死亡的重要原因。评价苯那普利给药对CKD犬延长生存期的有效性和安全性。49只客户养的慢性肾病犬在一项前瞻性、多中心、盲法临床试验中，将狗随机分配至苯那普利（0.25至<0.5 mg/kg）或安慰剂组，每日一次，持续长达2年。主要终点变量为肾脏存活时间，定义为从入选研究至治疗失败终点（死亡或安乐死或需要给予与肾衰竭相关的胃肠外液体）的时间。在所有犬中，未检测到苯那普利与安慰剂相比在肾存活时间方面的获益;苯那普利组的中位（95%置信区间（CI））存活时间为305（53-575）天，安慰剂组为287（152-不可用）天（P = .53）。在亚组中，苯那普利组的肾存活时间与安慰剂组相比并没有显著延长：初始尿蛋白肌酐比（UPC）>0.5的风险比（95% CI）为0.50（0.21-1.22），P = 0.12;初始UPC > 0.5且血浆肌酐≤440 μmol/L的风险比（95% CI）为0.38（0.12-1.19），P = 0.080。与安慰剂相比，苯那普利治疗后，尿蛋白（UPC评估）显著降低（P = 0.0032）。两组之间的临床体征或不良事件频率无显著差异。苯那普利可显著降低CKD犬的蛋白尿。招募的犬数量不足，无法得出生存时间的结论。
Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. Forty‐nine client‐owned dogs with CKD. Dogs were randomized to benazepril (0.25 to <0.5 mg/kg) or placebo once daily for up to 2 years in a prospective, multicenter, blinded clinical trial. The primary endpoint variable was the renal survival time, defined as the time from inclusion in the study to the treatment failure endpoint of death or euthanasia or need for administration of parenteral fluids related to renal failure. No benefit of benazepril versus placebo was detected for renal survival time in all dogs; median (95% confidence interval (CI)) survival times were 305 (53–575) days in the benazepril group and 287 (152‐not available) in the placebo group (P = .53). Renal survival times were not significantly longer with benazepril compared to placebo for subgroups: hazard ratios (95% CI) were 0.50 (0.21–1.22) with P = .12 for initial urine protein‐to‐creatinine ratio (UPC) >0.5, and 0.38 (0.12–1.19) with P = .080 for initial UPC >0.5 plus plasma creatinine ≤440 μmol/L. Proteinuria, assessed from the UPC, was significantly (P = .0032) lower after treatment with benazepril compared to placebo. There were no significant differences between groups for clinical signs or frequencies of adverse events. Benazepril significantly reduced proteinuria in dogs with CKD. Insufficient numbers of dogs were recruited to allow conclusions on survival time.
登录
查看更多内容
影响因子：
2.6
作者：
Garosi, L;McConnell, JF;Schatzberg, SJ
通讯作者：
Schatzberg, SJ
影响因子：
2.6
作者：
Chakrabarti, S.;Syme, H. M.;Elliott, J.
通讯作者：
Elliott, J.
影响因子：
6.2
作者：
Morrone, LF;DiPaolo, S;Schena, FP
通讯作者：
Schena, FP
影响因子：
158.5
作者：
Maschio, G;Alberti, D;Rainisio, M
通讯作者：
Rainisio, M
DOI：
10.2460/javma.2003.222.322
发表时间：
2003-02-01
期刊：
JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION
影响因子：
--
作者：
Jacob, F;Polzin, DJ;Swanson, LL
通讯作者：
Swanson, LL